Pentagon temporarily rescinds new testosterone screening guidance one day after release
The Pentagon has temporarily withdrawn the clinical guidelines it released only a day earlier for screening male service members age 30 and older for testosterone deficiency, saying the protocols are being updated before final clinical guidance is issued.
The pullback does not end Defense Secretary Pete Hegseth’s push to make hormone screening a routine part of military health assessments. The Defense Department said the interim guidance remains in effect while the new version is assembled.
“The Department remains committed to addressing hormone deficiencies, protecting the long-term health of its Service members, and enabling peak operational performance,” the department said in a statement. “The ‘Interim Guidance on Testosterone Deficiency Screenings for Active Duty and Reserve Component Personnel’ remains in effect. The final clinical guidance will be issued shortly.”
The guidelines originated with the Defense Health Agency and would apply to active-duty troops and reservists ages 30 and over. Screenings and blood tests were expected to become part of regular health assessments, not a separate or optional medical process. Service members found to have hypogonadism, or low testosterone, were to receive follow-up testing and treatment, including testosterone replacement therapy, if medically recommended. Male service members under 30 would be offered optional annual screenings, and female service members would be asked about symptoms of hormonal dysregulation and referred for further assessment when needed.
Why the Defense Department stepped back after one day is not explained in the announcement. The quick reversal may reflect normal administrative review catching up with a policy that moved unusually fast from announcement to implementation. It also underscores how clinical guidance, once drafted, can require a more deliberate review than the political rollout of the initiative suggested.
Hegseth called for the change earlier this summer. Two and a half months after it was announced, the policy had become a visible piece of his broader focus on military readiness. He introduced the effort in a social media video titled “The High-T Department of War” and has framed it as a health issue rather than an attempt to enhance performance.
“This initiative, it’s not about artificial enhancement. It’s about restoring and optimizing your natural capabilities, protecting your longevity and ensuring you have the biological foundation required to sustain the fight,” Hegseth said.
In July, he said service members would keep control over treatment decisions. “If treatment is recommended for service members, it’s entirely your choice to receive testosterone replacement therapy,” he said.
The Defense Department has said the goal is to “invest in the health of its warfighters, strengthen their performance, and maximize force readiness.” The clinical guidance calls testosterone “a critical biological marker for Warfighter readiness, directly impacting physical strength, bone density, aerobic fitness, depressive symptoms, and cardiovascular health,” and warns that service members may be especially vulnerable to declining levels.
That concern is not new in military medicine. Army Maj. Theodore Crisostomo-Wynne, a urologist at Madigan Army Medical Center, told a Food and Drug Administration panel last year that “the high operations tempo and high stress that these service members go through can actually decrease testosterone, sometimes acutely and sometimes even in the long term.”
Researchers have also used the term Operator Syndrome to describe a broader set of medical issues seen in high-stress military populations, including special operations forces. Crisostomo-Wynne last year attributed part of that pattern to “chronic stress, blast exposure, traumatic brain injuries and sleep disruptions.”
The temporary rescission leaves practical questions unresolved: whether the screening will arrive on schedule, how clinicians should interpret cases during the update, and whether the final guidance will make material changes to the scope or treatment pathway. The Pentagon has not given a date for the revised document. For now, the policy intent remains public and active, but the medical order that was meant to carry it into military clinics is back in review.